Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
A.P. Pharma Reports Third Quarter 2009 Financial Results
A.P. Pharma Reports Second Quarter 2009 Financial Results
A.P. Pharma Receives Nasdaq Notice of Non-Compliance; Company to Request Hearing
A.P. Pharma Announces FDA Acceptance of APF530 New Drug Application for Chemotherapy-Induced Nausea and Vomiting
A.P. Pharma Receives Extension for Nasdaq Listing Compliance
A.P. Pharma Presents APF530 Phase 3 Data at Annual Meeting of the American Society of Clinical Oncology
A.P. Pharma Announces Additional Restructuring Effort
A.P. Pharma Submits New Drug Application for APF530 in Chemotherapy-Induced Nausea and Vomiting
APF530 Phase 3 Data for Chemotherapy-Induced Nausea and Vomiting to be Presented at American Society of Clinical Oncology 2009 Annual Meeting
Tang Capital Partners, LP and Perceptive Life Sciences Master Fund Ltd. Urge the Shareholders of Penwest Pharmaceuticals Co. To Vote for Their Shareholder Proposals
A.P. Pharma Reports First Quarter 2009 Financial Results
A.P. Pharma Receives Nasdaq Stockholder Equity Notification
A.P. Pharma Announces Fourth Quarter and Year-End 2008 Financial Results and Provides Update on APF530 NDA
A.P. Pharma Appoints John B. Whelan as Chief Financial Officer
A.P. Pharma Revises Target Date for APF530 NDA
A.P. Pharma Reports Results for the Third Quarter 2008
A.P. Pharma to Present at Rodman & Renshaw 10th Annual Healthcare Conference on November 12
A.P. Pharma to Hold 2008 Third Quarter Financial Results Conference Call November 5
A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV
A.P. Pharma to Hold APF530 Phase 3 Trial Results Conference Call September 30 at 9:00 a.m. Eastern
A.P. Pharma Reports Results for the Second Quarter 2008
A.P. Pharma to Hold 2008 Second Quarter Financial Results Conference Call August 14
A.P. Pharma Announces Stock Option Grant
A.P. Pharma Appoints Ronald J. Prentki as President, Chief Executive Officer and Member of Its Board of Directors
A.P. Pharma Completes Enrollment in Phase 3 Trial of APF530
A.P. Pharma Reports Results for the First Quarter 2008 - May 27 2008 12:53AM
A.P. Pharma to Hold 2008 First Quarter Financial Results Conference Call May 15 - Jun 1 2008 7:11AM
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
